Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Request a Policy / Feedback
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.32
    OpenPayerPolicy UpdatesPharmacy & Specialty DrugsAloha Care step therapy & prior auth Coverage | Op…
    Ask Trek AI about this page
    CurrentAloha CarePolicy N/A

    2026 AlohaCare Advantage Plus (HMO D-SNP) Drugs with Step Therapy Requirements

    Customize your policy alerts

    Sign up for all Aloha Care policy alerts

    Know when Aloha Care releases new policies or updates existing guidance.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    Defines Aloha Care's step therapy requirements for specific drugs under the 2026 AlohaCare Advantage Plus (HMO D-SNP) plan, specifying required prior therapies before coverage is authorized for listed products.

    Policy Summary
    PayerAloha Care
    Policy2026 AlohaCare Advantage Plus (HMO D-SNP) Drugs with Step Therapy Requirements
    Policy CodePolicy N/A
    Change TypeAdministrative — no material clinical changes
    Effective DateAug 1, 2026
    Last ReviewJul 2, 2026
    Next Review DateJul 2, 2026
    Key ActionDocument prior trials of the required preferred therapies (for example, trial of topical fluorouracil or imiquimod before Diclofenac Sodium GEL 3%) when submitting prior authorization.
    SourceLink
    POLICY UPDATE CHANGES

    No material clinical or coverage changes in this revision.

    9+distinct drug/group entries
    2drugs with step entries
    1Rytary prior trial
    1Zonisade prior trial

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    allowedZonisade continuation

    Coverage Criteria and Step Requirements

    Actinic keratosis — Initial step requirement

    Covered when the following prior therapy is documented

    Actinic keratosis (Diclofenac Sodium GEL 3%): Trial of either topical fluorouracil OR topical imiquimod1 trial

    Approve for continuation of prior therapy

    Antidepressants — Initial step requirement

    Covered when prior trials of formulary generics are documented

    Antidepressants (Emsam, Exxua, Exxua Titration Pack, Fetzima, Fetzima Titration Pack): Trial of two generics from: bupropion, mirtazapine, citalopram, desvenlafaxine succinate ER, duloxetine, escitalopram, fluoxetine, fluvoxamine, paroxetine, sertraline, venlafaxine hydrochloride2 trials

    Approve for continuation of prior therapy

    Atypical antipsychotics — Initial step requirement

    Covered when prior trials of formulary atypical antipsychotics are documented

    Atypical antipsychotics (Fanapt, Fanapt Titration Pack A, Lybalvi, Secuado): Trial of two of the following oral generic formulary agents: asenapine, aripiprazole, olanzapine, paliperidone, quetiapine, risperidone, ziprasidone2 trials

    Approve for continuation of prior therapy

    Invega Hafyera — Initial step requirement

    Covered when prior long-acting formulations are tried (new starts only)

    Invega Hafyera: Trial of one of: Invega Sustenna OR Invega Trinza for new starts1 trial

    Step applies to new starts only; Approve for continuation of prior therapy

    Relistor — Initial step requirement

    Covered when prior laxative/agent trials are documented

    Relistor: Trial of one of: lubiprostone, Constulose, Enulose, Generlac, lactulose, OR Movantik1 trial

    Rytary - Initial step requirement

    Rytary - Covered when the following are met:

    Rytary prior trial: Trial of one generic carbidopa/levodopa containing formulation

    Zonisade - Initial step requirement

    Zonisade - Covered when the following are met for new starts:

    Zonisade prior trial (new starts): Trial of generic zonisamide capsule

    Step applies to new starts only. Approve for continuation of prior therapy.

    For Invega Hafyera, the step therapy requirement applies only to new starts. Coverage for new therapy requires documentation of a trial of either Invega Sustenna or Invega Trinza. If the member is already receiving Invega Hafyera as ongoing therapy, the step requirement does not apply and continuation of prior therapy is approved.

    For Zonisade new starts, coverage requires documentation of a trial of a generic zonisamide capsule. The step therapy requirement does not apply to members already receiving zonisamide; continuation of prior zonisamide therapy is approved.

    Provider Actions, Prior Authorization, and Documentation

    Prior Authorization

    Actinic keratosis — prior authorization

    Prior authorization requires documentation that the member trialed topical fluorouracil or topical imiquimod before Diclofenac Sodium GEL 3% will be approved.

    Prior Authorization

    Antidepressants — prior authorization

    Prior authorization requires documentation of trials of two generic formulary antidepressants (from the listed agents) before approving nonpreferred antidepressant products; continuation of prior therapy is approved.

    • Required trials from: bupropion; mirtazapine; citalopram; desvenlafaxine succinate ER; duloxetine; escitalopram; fluoxetine; fluvoxamine; paroxetine; sertraline; venlafaxine hydrochloride
    Prior Authorization

    Atypical antipsychotics — prior authorization

    Initial Therapy Criteria (Step 1 Requirements)

    Diclofenac Sodium GEL 3% — initial therapy

    Diclofenac Sodium GEL 3% initial: Trial of topical fluorouracil OR topical imiquimod required1 trial

    Antidepressants — initial therapy

    Emsam/Exxua/Fetzima initial: Trial of two generics from listed antidepressants required2 trials

    Approve continuation of prior therapy

    Atypical antipsychotics — initial therapy

    Continuation Therapy Guidance

    Actinic keratosis — continuation

    Continuation guidance when prior therapy exists

    Diclofenac Sodium GEL 3%: Approve for continuation of prior therapy

    Step required for new starts only

    Antidepressants — continuation

    Continuation guidance for antidepressants

    Affected antidepressants: Approve for continuation of prior therapy

    Step applies to new starts; continuation allowed

    Atypical antipsychotics — continuation

    Continuation guidance for atypical antipsychotics

    Step Therapy Summary Table

    Drug / GroupStep requirement (step 1)Coverage status
    Diclofenac Sodium GEL 3%Trial of either topical fluorouracil OR topical imiquimodCovered with criteria
    Drug / GroupStep requirement (step 1)Coverage status
    Emsam; Exxua; Exxua Titration Pack; Fetzima; Fetzima Titration PackTrial of two generics from: bupropion, mirtazapine, citalopram, desvenlafaxine succinate ER, duloxetine, escitalopram, fluoxetine, fluvoxamine, paroxetine, sertraline, venlafaxine hydrochlorideCovered with criteria (approve continuation of prior therapy)
    Drug / GroupStep requirement (step 1)Coverage status
    Fanapt; Fanapt Titration Pack A; Lybalvi; SecuadoTrial of two oral generic formulary atypical antipsychotic agents: asenapine, aripiprazole, olanzapine, paliperidone, quetiapine, risperidone, ziprasidoneCovered with criteria (approve continuation of prior therapy)
    Drug / GroupStep requirement (step 1)Coverage status
    Invega HafyeraTrial of one of: Invega Sustenna OR Invega Trinza (step applies to new starts only)Covered with criteria (step does not apply to continuation of prior therapy)
    Drug / GroupStep requirement (step 1)Coverage status
    RelistorTrial of one of: lubiprostone, Constulose, Enulose, Generlac, lactulose, OR MovantikCovered with criteria
    Drug / GroupStep requirement (step 1)Coverage status
    RytaryTrial of one generic carbidopa/levodopa containing formulationCovered with criteria
    Drug / GroupStep requirement (step 1)Coverage status
    ZonisadeTrial of a generic zonisamide capsule (step applies to new starts only)Covered with criteria (approve continuation of prior therapy)

    Background

    This policy defines Aloha Care’s step therapy requirements for select drugs under the 2026 AlohaCare Advantage Plus (HMO D‑SNP) plan. It specifies that certain nonpreferred products require documented trials of preferred alternatives before coverage is authorized for new starts (for example, a trial of Invega Sustenna or Invega Trinza before Invega Hafyera, or a trial of a generic zonisamide capsule before Zonisade). Where noted, these step requirements apply to new starts only; members already on the listed therapy are generally eligible for continuation without re‑stepping.

    Definitions

    Step therapy definition
    DefinitionA coverage policy requiring a trial of one or more preferred medications before a nonpreferred medication will be approved.
    PurposeTo require documented use of specified preferred therapies (step 1) before authorizing listed nonpreferred drugs, reducing unnecessary use of higher‑cost or nonpreferred agents.
    Typical requirementOne or more documented trials of listed preferred agents (e.g., trial of topical fluorouracil OR topical imiquimod before Diclofenac Sodium GEL 3%).
    ApplicationApplies to new therapy starts unless otherwise noted; continuation of prior therapy is approved when policy specifies continuation allowance.
    Provider actionDocument prior trials of the required agent(s) when submitting prior authorization to avoid denial or delay of coverage.
    Policy Summary
    PayerAloha Care
    Policy2026 AlohaCare Advantage Plus (HMO D-SNP) Drugs with Step Therapy Requirements
    Policy CodePolicy N/A
    Change TypeAdministrative — no material clinical changes
    Effective DateAug 1, 2026
    Last ReviewJul 2, 2026
    Next Review DateJul 2, 2026
    Key ActionDocument prior trials of the required preferred therapies (for example, trial of topical fluorouracil or imiquimod before Diclofenac Sodium GEL 3%) when submitting prior authorization.
    SourceLink
    On This Page
    Coverage Criteria and Step RequirementsProvider Actions, Prior Authorization, and DocumentationInitial Therapy Criteria (Step 1 Requirements)Continuation Therapy GuidanceStep Therapy Summary TableBackgroundDefinitions

    Prior authorization requires documentation of trials of two oral generic formulary atypical antipsychotics (from the listed agents) before approving specified atypical antipsychotic products; continuation of prior therapy is approved.

    • Required trials from: asenapine; aripiprazole; olanzapine; paliperidone; quetiapine; risperidone; ziprasidone
    Prior Authorization

    Invega Hafyera — prior authorization

    For new starts, prior authorization requires documentation of a trial of Invega Sustenna or Invega Trinza before Invega Hafyera will be approved; continuation of prior therapy is approved without step.

    • Step applies to new starts only; approve continuation of prior therapy
    Prior Authorization

    Relistor — prior authorization

    Prior authorization requires documentation of a trial of one of the specified alternatives (lubiprostone, Constulose, Enulose, Generlac, lactulose, or Movantik) before Relistor will be approved.

    Prior Authorization

    Rytary — prior authorization

    Prior authorization requires documentation that the member trialed one generic carbidopa/levodopa containing formulation before Rytary will be approved.

    Prior Authorization

    Zonisade — prior authorization

    For new starts, prior authorization requires documentation of a trial of a generic zonisamide capsule before Zonisade will be approved; existing therapy may be approved for continuation without re-stepping.

    • Step applies to new starts only; approve continuation of prior zonisamide therapy
    Step Therapy

    Actinic keratosis — step requirement

    A trial of either topical fluorouracil OR topical imiquimod is required before Diclofenac Sodium GEL 3% for actinic keratosis.

    • Requirement: 1 trial of either topical fluorouracil or topical imiquimod
    Step Therapy

    Antidepressants — step requirement

    A trial of two generic formulary antidepressants (from the listed agents) is required prior to approving specified nonpreferred antidepressant products.

    • Requirement: 2 trials from bupropion; mirtazapine; citalopram; desvenlafaxine succinate ER; duloxetine; escitalopram; fluoxetine; fluvoxamine; paroxetine; sertraline; venlafaxine hydrochloride
    Step Therapy

    Atypical antipsychotics — step requirement

    A trial of two oral generic formulary atypical antipsychotics (from the listed agents) is required prior to approving specified atypical antipsychotics.

    • Requirement: 2 trials from asenapine; aripiprazole; olanzapine; paliperidone; quetiapine; risperidone; ziprasidone
    Step Therapy

    Invega Hafyera — step requirement

    For new starts, a trial of Invega Sustenna or Invega Trinza is required before Invega Hafyera will be approved; this step does not apply to continuation of prior therapy.

    • Requirement applies to new starts only
    Step Therapy

    Relistor — step requirement

    A trial of lubiprostone, Constulose, Enulose, Generlac, lactulose, or Movantik is required prior to approval of Relistor.

    Step Therapy

    Rytary — step requirement

    A trial of one generic carbidopa/levodopa containing formulation is required (step 1) before Rytary will be approved.

    • Requirement: trial of one generic carbidopa/levodopa formulation
    Step Therapy

    Zonisade — step requirement

    For new starts, a trial of a generic zonisamide capsule is required before Zonisade will be approved; the step does not apply to members continuing prior zonisamide therapy.

    • Step applies to new starts only; approve continuation of prior therapy
    Documentation Required

    Actinic keratosis — documentation

    Document the prior trial of topical fluorouracil or topical imiquimod when requesting Diclofenac Sodium GEL 3% for actinic keratosis.

    Documentation Required

    Antidepressants — documentation

    Document trials of two generics from the listed antidepressant agents when requesting affected antidepressant products; continuation of prior therapy is allowed.

    Documentation Required

    Atypical antipsychotics — documentation

    Document trials of two oral generic formulary atypical antipsychotics when requesting affected atypical antipsychotic products; continuation of prior therapy is allowed.

    Documentation Required

    Invega Hafyera — documentation

    For Invega Hafyera new starts, document a trial of Invega Sustenna or Invega Trinza; if therapy is a continuation, document that to approve without step.

    Documentation Required

    Relistor — documentation

    Document prior use of the designated laxatives or agents (lubiprostone, Constulose, Enulose, Generlac, lactulose, Movantik) before requesting Relistor.

    Documentation Required

    Rytary — documentation

    Document that the member trialed one generic carbidopa/levodopa formulation when requesting Rytary.

    Documentation Required

    Zonisade — documentation

    For new starts of Zonisade, document that the member trialed a generic zonisamide capsule; document continuation of prior therapy to approve without step.

    Denial Risk

    Diclofenac GEL — denial risk

    Coverage will be denied for Diclofenac Sodium GEL 3% until a trial of either topical fluorouracil or topical imiquimod is documented.

    Denial Risk

    Antidepressants — denial risk for step requirement

    Coverage will be denied unless trials of two listed generic antidepressants are documented prior to approving Emsam, Exxua, Exxua Titration Pack, Fetzima, or Fetzima Titration Pack.

    Denial Risk

    Atypical antipsychotics — denial risk for step requirement

    Coverage will be denied unless trials of two oral generic formulary atypical antipsychotics are documented before Fanapt, Fanapt Titration Pack A, Lybalvi, or Secuado are approved.

    Denial Risk

    Invega Hafyera — denial risk for new starts

    Coverage for new starts of Invega Hafyera will be denied unless a trial of Invega Sustenna or Invega Trinza is documented; continuation of prior therapy is approved.

    Denial Risk

    Relistor — denial risk

    Coverage will be denied unless a trial of lubiprostone, Constulose, Enulose, Generlac, lactulose, or Movantik is documented prior to Relistor.

    Denial Risk

    Rytary — denial risk for prior trial

    If a trial of one generic carbidopa/levodopa containing formulation is not documented for Rytary, coverage may be denied.

    Denial Risk

    Zonisade — denial risk for prior trial

    If a trial of a generic zonisamide capsule is not documented for new starts of Zonisade, coverage may be denied.

    Fanapt/Lybalvi/Secuado initial: Trial of two oral generic formulary atypical antipsychotics required2 trials

    Approve continuation of prior therapy

    Invega Hafyera — initial therapy

    Invega Hafyera initial: Trial of Invega Sustenna OR Invega Trinza required for new starts1 trial

    Step applies to new starts only; continuation approved

    Relistor — initial therapy

    Relistor initial: Trial of lubiprostone, Constulose, Enulose, Generlac, lactulose, OR Movantik required1 trial

    Rytary initial therapy

    Rytary initial: Trial of one generic carbidopa/levodopa containing formulation required before Rytary for new starts.

    Zonisade initial therapy

    Zonisade initial: Trial of a generic zonisamide capsule required for new starts of Zonisade.

    Step applies to new starts only; approve continuation of prior therapy.

    Affected atypical antipsychotics: Approve for continuation of prior therapy

    Step applies to new starts; continuation allowed

    Invega Hafyera — continuation

    Continuation guidance for Invega Hafyera

    Invega Hafyera: Approve for continuation of prior therapy

    Step applies to new starts only

    Zonisade continuation

    Continuation of prior therapy

    Zonisade continuation: Approve for continuation of prior zonisamide therapy; step therapy requirement does not apply to ongoing treatment.